Prime Medicine, Inc. (PRME) Revenue by Segment & Business Profile
Gene editing therapies for genetic diseases (clinical-stage, no approved products) was 100.0% of Prime Medicine, Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PRMEPrime Medicine, Inc.Follow PRME — free
—
Price chart with a free account
- Market cap
- 665.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
What the company does
Prime Medicine, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $4.1 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Platform (mRNA / RNAi / gene)
Prime Medicine, Inc. — questions
- What does Prime Medicine, Inc. do?
- Prime Medicine, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $4.1 million as of 2026-06-30.
- How does Prime Medicine, Inc. make money?
- By the lines it reports in its SEC filings: Gene editing therapies for genetic diseases (clinical-stage, no approved products) 100.0% of revenue.
Every figure on this page comes from Prime Medicine, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.